Assenagon Asset Management S.A. reduced its position in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 83.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,617 shares of the company's stock after selling 289,575 shares during the period. Assenagon Asset Management S.A. owned about 0.10% of Design Therapeutics worth $349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently added to or reduced their stakes in DSGN. Almitas Capital LLC increased its position in shares of Design Therapeutics by 22.1% in the second quarter. Almitas Capital LLC now owns 1,253,248 shares of the company's stock valued at $4,198,000 after buying an additional 227,180 shares in the last quarter. Geode Capital Management LLC increased its holdings in Design Therapeutics by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 758,550 shares of the company's stock worth $4,081,000 after acquiring an additional 50,579 shares in the last quarter. FMR LLC raised its position in Design Therapeutics by 922.8% during the third quarter. FMR LLC now owns 828,665 shares of the company's stock worth $4,458,000 after acquiring an additional 747,649 shares during the period. Barclays PLC lifted its holdings in Design Therapeutics by 34.2% during the third quarter. Barclays PLC now owns 96,635 shares of the company's stock valued at $520,000 after purchasing an additional 24,602 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of Design Therapeutics by 66.9% in the second quarter. Point72 Asset Management L.P. now owns 990,801 shares of the company's stock valued at $3,319,000 after purchasing an additional 397,285 shares during the period. 56.64% of the stock is owned by hedge funds and other institutional investors.
Design Therapeutics Stock Down 2.9 %
Shares of DSGN stock traded down $0.15 on Friday, reaching $4.97. 101,461 shares of the company were exchanged, compared to its average volume of 178,865. Design Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $7.77. The business has a 50-day moving average price of $5.77 and a 200 day moving average price of $5.33.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.03. Equities analysts forecast that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.
About Design Therapeutics
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Further Reading
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
